{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-059435","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.333656+00:00","generated_at":"2026-05-19T09:14:15.968079+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Nuvectis Pharma shareholders elect director, ratify auditor at 2025 annual meeting","bullets":["Quorum of 14,605,167 shares (61.86%) present out of 23,606,443 outstanding shares.","Class III director James Oliviero elected with 9,882,555 votes for, 240,327 against, 782 abstentions.","Ratification of Kesselman & Kesselman as independent auditor approved with 14,561,983 votes for, 40,324 against.","All proposals passed as detailed in the April 28, 2025 proxy statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-059435","json":"https://secwatch.observer/filing/0001104659-25-059435.json","markdown":"https://secwatch.observer/filing/0001104659-25-059435.md","text":"https://secwatch.observer/filing/0001104659-25-059435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/0001104659-25-059435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925059435/tm2518009d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T09:14:15.968079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}